pre-IPO PHARMA

cullgen PRESS RELEASE ARCHIVE

Jun 17, 2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer


Jun 10, 2021

Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development


Feb 25, 2021

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform


Oct 16, 2020

Cullgen Announces “Featured Article” Publication of First in Class TRK Protein Degraders in Journal of Medicinal Chemistry


Apr 7, 2020

Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry



Apr 10, 2019

Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders


Jul 18, 2018

Cullgen Announces Expanded Scientific Advisory Board


Jul 18, 2018


Apr 2, 2018

Cullgen Announces ALK PROTACs Publication by Its Co-founders in the European Journal of Medicinal Chemistry


Mar 1, 2018

Cullgen Announces Series Seed Financing



Google Analytics Alternative